舒肝散结汤治疗子宫肌瘤的系统评价与Meta分析
本系统评价与Meta分析旨在评估舒肝散结汤联合米非司酮或醋酸亮丙瑞林治疗子宫肌瘤的有效性与安全性。共纳入12项RCT(952例受试者),结果显示联合治疗组的总有效率显著优于单用西药组[RR=1.26, 95% CI (1.19, 1.34), P<0.00001]。但纳入研究方法学质量较差且异质性高,结论需谨慎解读。
要点
- 舒肝散结汤联合米非司酮或亮丙瑞林可提高子宫肌瘤治疗的总有效率。
- 联合治疗可能缩小肌瘤体积并调节性激素水平,但证据质量有限。
- 现有证据方法学质量低、异质性高,临床决策需结合个体情况。
核心结论
- 舒肝散结汤联合米非司酮或醋酸亮丙瑞林治疗子宫肌瘤可提高临床有效率,并可能缩小肌瘤体积、调节性激素水平,但受限于纳入研究的方法学质量差和高异质性,结论需谨慎解读。
研究设计与样本
- 系统评价与Meta分析,检索8个数字医学数据库至2024年7月,纳入12项随机对照试验(RCT),共952例受试者,比较舒肝散结汤联合米非司酮或醋酸亮丙瑞林与单用米非司酮或醋酸亮丙瑞林。
主要发现
- 舒肝散结汤联合米非司酮或醋酸亮丙瑞林治疗子宫肌瘤的总有效率[RR=1.26, 95% CI (1.19, 1.34), P<0.00001]显著优于单用米非司酮或醋酸亮丙瑞林组(P<0.05)。
- 原文结论指出联合治疗可改善临床有效率、缩小肌瘤体积并调节性激素水平,但未报告具体数值。
关键数值与推荐
- 主要结局为临床有效率(CER),联合治疗组对比单用米非司酮或醋酸亮丙瑞林组的RR=1.26,95% CI (1.19, 1.34),P<0.00001。
- 次要结局包括子宫肌瘤体积(UFV)、子宫体积(UV)、血清性激素水平(FSH、LH、E2、P)及中医证候积分(TSS),原文未报告具体数值。
临床怎么用
- 对于子宫肌瘤患者,可考虑在米非司酮或醋酸亮丙瑞林治疗基础上联合舒肝散结汤以提高临床有效率。
- 临床决策时应充分告知患者现有证据的方法学局限性及高异质性,并结合个体情况谨慎使用。
局限性
- 纳入试验的方法学质量较差且异质性高,导致结论需谨慎解读。
- 未来需开展采用标准化治疗方案、延长随访时间及全面安全性评估的严谨RCT以确认疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Shugan Sanjie Decoction (SGSJ) is a commonly used Chinese medicine prescription for the treatment of uterine fibroids (UFs). However, there is still a lack of evidence for its effects and safety. To systematically assess the efficacy and safety of SGSJ in conjunction with Mifepristone [MFP] or Leuprolide acetate [LA] for the treatment of UFs, thereby providing a reference for clinical medication. OBJECTIVE: To systematically assess the efficacy and safety of SGSJ in combination with MFP or LA for the treatment of UFs, thereby providing a basis for clinical medication decisions. METHODS: Eight digital medical databases were systematically searched to identify randomized controlled trials (RCTs) evaluating the use of SGSJ combined with MFP or LA for the treatment of UFs. The search spanned from the inception of each database to July 2024. Risk of Bias (ROB) 2.0 and RevMan 5.3 software were utilized for systematic review and meta-analysis. Eligible studies comprised RCTs comparing SGSJ plus MFP or LA with MFP or LA alone. The primary outcome was the Clinical Effective Rate (CER). Secondary outcomes included (1) Uterine Fibroid Volume (UFV) (2), Uterine Volume (UV) (3), Serum Sex Hormone Levels [Follicle-Stimulating Hormone (FSH), Luteinizing Hormone (LH), Estradiol (E2), Progesterone (P)], and (4) Traditional Chinese Medicine Syndrome Scores (TSS). RESULTS: The meta-analysis comprised 12 RCTs with 952 participants. The results of meta-analysis showed that the total effective rate of SGSJ or combined with MFP or LA in the treatment of UFs [RR = 1.26, 95% CI (1.19, 1.34), P < 0.00001], which was statistically significant compared with the MFP or LA group and superior to the MFP or LA group (P < 0.05). CONCLUSION: At present, there are evidence shows that SGSJ combined with MFP or LA improves CER, reduces UFV, and modulates sex hormone levels. However, due to the poor methodological quality and high heterogeneity of the included trials, our conclusions should be interpreted with caution. Future studies should prioritize rigorous RCTs with standardized treatment protocols, extended follow-up, and comprehensive safety assessments to identify SGSJ as a reliable treatment option for UFs. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024506017.
引用
- Zhang Y, Wei J, Gao C, et al. The efficacy and safety of Chinese herbal medicine Shugan Sanjie decoction in the treatment of uterine fibroids: a systematic review and meta-analysis. Front Pharmacol. 2025. PMID: 40313615. doi:10.3389/fphar.2025.1508015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。